AR126157A1 - RECEPTORS THAT PROVIDE DIRECTED COSTIMULATION FOR ADOPTIVE CELLULAR THERAPY - Google Patents
RECEPTORS THAT PROVIDE DIRECTED COSTIMULATION FOR ADOPTIVE CELLULAR THERAPYInfo
- Publication number
- AR126157A1 AR126157A1 ARP220101580A ARP220101580A AR126157A1 AR 126157 A1 AR126157 A1 AR 126157A1 AR P220101580 A ARP220101580 A AR P220101580A AR P220101580 A ARP220101580 A AR P220101580A AR 126157 A1 AR126157 A1 AR 126157A1
- Authority
- AR
- Argentina
- Prior art keywords
- domain
- costar
- signaling
- sequence
- linked
- Prior art date
Links
- 238000002659 cell therapy Methods 0.000 title 1
- 230000004940 costimulation Effects 0.000 title 1
- 230000011664 signaling Effects 0.000 abstract 11
- 239000012634 fragment Substances 0.000 abstract 4
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 abstract 3
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 abstract 3
- 102000037865 fusion proteins Human genes 0.000 abstract 3
- 108020001507 fusion proteins Proteins 0.000 abstract 3
- 230000003834 intracellular effect Effects 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 108010083359 Antigen Receptors Proteins 0.000 abstract 2
- 102000006306 Antigen Receptors Human genes 0.000 abstract 2
- 101150013553 CD40 gene Proteins 0.000 abstract 2
- 102000003735 Mesothelin Human genes 0.000 abstract 2
- 108090000015 Mesothelin Proteins 0.000 abstract 2
- 102000004393 TNF receptor-associated factor 2 Human genes 0.000 abstract 2
- 108090000925 TNF receptor-associated factor 2 Proteins 0.000 abstract 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 abstract 2
- 238000011467 adoptive cell therapy Methods 0.000 abstract 2
- 230000027455 binding Effects 0.000 abstract 2
- 230000000139 costimulatory effect Effects 0.000 abstract 2
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 abstract 1
- 102100035108 High affinity nerve growth factor receptor Human genes 0.000 abstract 1
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 abstract 1
- 101000596894 Homo sapiens High affinity nerve growth factor receptor Proteins 0.000 abstract 1
- 102000004399 TNF receptor-associated factor 3 Human genes 0.000 abstract 1
- 108090000922 TNF receptor-associated factor 3 Proteins 0.000 abstract 1
- 102000003714 TNF receptor-associated factor 6 Human genes 0.000 abstract 1
- 108090000009 TNF receptor-associated factor 6 Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical group C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000009870 specific binding Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Algunas formas de realización proporcionadas en la presente son un receptor de antígeno coestimulador quimérico (CoStAR), útil en la terapia celular adoptiva (ACT), y células que comprenden el CoStAR. En algunas formas de realización, el CoStAR puede actuar como modulador de la actividad celular aumentando las respuestas a antígenos definidos. En algunas formas de realización, se proporcionan además el CoStAR y/o proteínas de fusión, ácidos nucleicos que codifican el CoStAR y sus usos terapéuticos. Reivindicación 1: Un receptor de antígeno coestimulador quimérico (CoStAR) que comprende: un dominio de unión extracelular que se une al antígeno carcinoembrionario (CEA), o un dominio de unión extracelular que se une a mesotelina (MSLN), ligado operativamente a un dominio transmembrana, y un primer dominio de señalización y un dominio intracelular de ICOS o un fragmento de señalización del mismo, o un primer dominio de señalización y un dominio intracelular de NTRK1 o un fragmento de señalización del mismo, o un primer dominio de señalización y un dominio intracelular de DAP10 o un fragmento de señalización del mismo, o un primer dominio de señalización y un dominio de señalización CD40 o un fragmento de señalización del mismo, o un primer dominio de señalización y uno o más de una secuencia de TRAF2 / TRAF3, una secuencia de TRAF6, una secuencia de TRAF2 o una secuencia de IProx. Reivindicación 18: Un ácido nucleico que codifica el CoStAR de una cualquiera de las reivindicaciones 1 a 17. Reivindicación 19: Un vector que comprende el ácido nucleico de la reivindicación 18. Reivindicación 20: Una célula que expresa el CoStAR de una cualquiera de las reivindicaciones 1 a 16. Reivindicación 27: Una proteína de fusión, en donde la proteína de fusión comprende: un dominio de unión específico para CEA ligado a; un dominio transmembrana que está ligado a; un dominio de ICOS que está ligado a; un dominio de señalización CD40.Some embodiments provided herein are a chimeric costimulatory antigen receptor (CoStAR), useful in adoptive cell therapy (ACT), and cells comprising the CoStAR. In some embodiments, CoStAR may act as a modulator of cellular activity by increasing responses to defined antigens. In some embodiments, CoStAR and/or fusion proteins, nucleic acids encoding CoStAR, and their therapeutic uses are further provided. Claim 1: A chimeric costimulatory antigen receptor (CoStAR) comprising: an extracellular binding domain that binds carcinoembryonic antigen (CEA), or an extracellular binding domain that binds mesothelin (MSLN), operably linked to a domain transmembrane, and a first signaling domain and an intracellular domain of ICOS or a signaling fragment thereof, or a first signaling domain and an intracellular domain of NTRK1 or a signaling fragment thereof, or a first signaling domain and a intracellular domain of DAP10 or a signaling fragment thereof, or a first signaling domain and a CD40 signaling domain or a signaling fragment thereof, or a first signaling domain and one or more of a TRAF2/TRAF3 sequence, a TRAF6 sequence, a TRAF2 sequence or an IProx sequence. Claim 18: A nucleic acid encoding the CoStAR of any one of claims 1 to 17. Claim 19: A vector comprising the nucleic acid of claim 18. Claim 20: A cell expressing the CoStAR of any one of claims 1 to 16. Claim 27: A fusion protein, wherein the fusion protein comprises: a CEA-specific binding domain linked to; a transmembrane domain that is linked to; an ICOS domain that is linked to; a CD40 signaling domain.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063301340P | 2020-01-20 | 2020-01-20 | |
| US202063222913P | 2020-06-16 | 2020-06-16 | |
| US202063211046P | 2020-06-16 | 2020-06-16 | |
| US202163211042P | 2021-06-16 | 2021-06-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126157A1 true AR126157A1 (en) | 2023-09-27 |
Family
ID=88197376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101580A AR126157A1 (en) | 2020-01-20 | 2022-06-15 | RECEPTORS THAT PROVIDE DIRECTED COSTIMULATION FOR ADOPTIVE CELLULAR THERAPY |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR126157A1 (en) |
-
2022
- 2022-06-15 AR ARP220101580A patent/AR126157A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202192024A1 (en) | RECEPTORS THAT PROVIDE TARGETS OF COSTIMULATION FOR ADOPTIONAL CELL THERAPY | |
| AR123004A1 (en) | RECEPTORS THAT PROVIDE USEFUL DIRECTED CO-ESTIMULATION FOR ADOPTIVE CELL THERAPY | |
| MX2020010235A (en) | Expression vectors for chimeric engulfment receptors, genetically modified host cells, and uses thereof. | |
| AR119683A1 (en) | ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS SPECIFIC TO ORPHAN RECEPTOR TYROSINE KINASE-LIKE 1 (ROR1) | |
| Tsong | Electroporation of cell membranes | |
| AR108427A1 (en) | CHEMERIC ANTIGEN AND T-CELL RECEPTORS AND METHODS OF USE | |
| EA202092093A1 (en) | COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS | |
| RU2022102624A (en) | COMPOSITIONS AND METHODS FOR CONNECTING TYPE I AND TYPE II EXTRACELLULAR DOMAIN AS HETEROLOGOUS CHIMERIC PROTEINS | |
| RU2012149858A (en) | OBTAINING HETEROMULTIMETRIC PROTEINS | |
| AR046833A1 (en) | ANTI-INTERLEUQUINA ANTIBODIES-10 | |
| NO2007013I1 (en) | Abatacept Fusion Protein Produced by Recombinant DNA Technology in Chinese Hamster Ovarian Cells A fusion protein consisting of the extracellular domain of human CTLA-4 linked to a modified Fc portion of human immunoglobulin G1 | |
| CN110461360A (en) | Improved antigen-binding receptors form | |
| Li et al. | Expansion of NK cells from PBMCs using immobilized 4-1BBL and interleukin-21 | |
| AR123005A1 (en) | CHIMERIC MOLECULES THAT PROVIDE TARGETED CO-ESTIMULATION USEFUL FOR ADOPTIVE CELL THERAPY | |
| CN109266667A (en) | Target the Chimeric antigen receptor and its application of CD5 | |
| JOP20180027A1 (en) | Chimeric polypeptides and methods of altering the membrane localization of the same | |
| Michou et al. | Optimization of recombinant membrane protein production in the engineered Escherichia coli strains SuptoxD and SuptoxR | |
| RU2017134506A (en) | PEPTIDES PRESENTATION SYSTEM ON CELL SURFACE | |
| AR125315A1 (en) | ARTIFICIAL COMBINED CELL DEATH POLYPEPTIDE/REPORTER SYSTEM FOR CHIMERA ANTIGEN RECEPTOR CELL AND ITS USES | |
| AR126157A1 (en) | RECEPTORS THAT PROVIDE DIRECTED COSTIMULATION FOR ADOPTIVE CELLULAR THERAPY | |
| EA202091713A1 (en) | BIOLOGICAL SYNTHESIS OF AMINO ACID CHAINS FOR OBTAINING PEPTIDES AND PROTEINS | |
| AR126463A1 (en) | CHIMERIC MOLECULES THAT PROVIDE TARGETED COSTIMULATION FOR ADOPTIVE CELLULAR THERAPY | |
| WO2022226054A3 (en) | Antigen presenting polypeptide complexes bearing tgf-beta and methods of use thereof | |
| BR112023019385A2 (en) | COMPOSITIONS COMPRISING NKG2D, CXCR2 AND DAP10/DAP12 FUSION POLYPEPTIDES AND THEIR METHODS OF USE | |
| WO2023141530A3 (en) | Receptors providing targeted costimulation for adoptive cell therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |